NCT03869684View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration

PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

February 25, 2019

Primary Completion Date

March 25, 2020

Study Completion Date

April 24, 2020

Conditions
Age-related Macular Degeneration
Interventions
DRUG

MT-0814

Randomly assigned dose

DRUG

Placebo

Placebo manufactured to mimic MT-0814

Trial Locations (13)

32308

Senju Investigational Site, Tallahassee

32701

Senju Investigational Site, Altamonte Springs

32901

Senju Investigational Site, Melbourne

33761

Senju Investigational Site, Clearwater

76012

Senju Investigational Site, Arlington

77030

Senju Investigational Site, Houston

77384

Senju Investigational Site, The Woodlands

78240

Senju Investigational Site, San Antonio

84107

Senju Investigational Site, Murray

85053

Senju Investigational Site, Phoenix

85381

Senju Investigational Site, Peoria

91107

Senju Investigational Site, Pasadena

92374

Senju Investigational Site, Redlands

Sponsors

Collaborators (1)

PPD Development, LP
All Listed Sponsors
collaborator

PPD Development, LP

INDUSTRY

lead

Senju Pharmaceutical Co., Ltd.

INDUSTRY